Fast-growing Indiana-based radiopharmaceutical developer and manufacturer appoints leading radiopharmaceutical executive to a new leadership role
SpectronRx, a leading radiopharmaceutical contract development, and manufacturing organization (CDMO), today announced that leading radiopharmaceutical executive Peter Webner has joined the company as Chief Operating Officer (COO). The news comes as the company continues to rapidly scale its operations across the U.S. and into key countries in Europe and Asia.
“Peter Webner is a well-respected and dynamic radiopharmaceutical executive joining us at an exciting time, and I’m pleased to welcome him to SpectronRx’s executive leadership team,” said John Zehner, CEO of SpectronRx. “Along with a proven track record of increasing revenue and bringing new products to market, Peter is also a subject matter expert with a deep understanding of our industry. And as we continue to innovate and grow, he will lead initiatives across our business units that drive exceptional results for our partners and patients globally.”
Peter Webner brings more than 35 years of nuclear medicine and radiopharmaceutical industry experience to SpectronRx, along with a proven track record of building and leading industry-focused companies through periods of tremendous growth and profitability. Prior to joining SpectronRx, Webner served as General Manager of Breast Oncology US and Global Executive MI Advisor at GE Healthcare. Webner joined GE Healthcare as part of the company’s acquisition of Zionexa, where he served as CEO. A licensed nuclear medicine technologist, Webner has also held key leadership positions in sales, marketing, product development, and operations at Zevacor Molecular and Zevacor Pharma, Eastern Isotopes, IBA Molecular, Positron Corporation, NCM and Mt. Sinai Medical Center in New York.
Webner holds numerous industry affiliations and certifications and earned his BA in Radiological Health Sciences at Manhattan College. He also completed advanced studies in product development at the Harvard Graduate School of Business.
“I am excited and honored to be joining the diverse and talented SpectronRx team at such an incredible time,” said SpectronRx’s new COO, Peter Webner. “As we continue to expand SpectronRx’s manufacturing footprint and extensive capabilities, we will remain steadfastly dedicated to what matters most; our people, our patients, and our partners. The important, life-saving radiopharmaceuticals that we develop and manufacture will help physicians to better diagnose and treat many diseases. It is an honor for me to help provide these critical, cutting-edge products to patients who need them.”
SpectronRx has more than 100 employees across four locations and provides services to organizations on three continents. The company works with pharmaceutical and healthcare organizations throughout the U.S., in select European countries, and in Asia, where it supplies isotopes to Japan. SpectronRx’s domestic operations include four locations, a 36,000 Sq. Ft. facility in South Bend, Indiana, a 60,000 Sq. Ft. facility in Indianapolis and more than 10 acres in Bunker Hill, Indiana, where it will produce Actinium-225 and a new location in Danbury, Connecticut.
To learn more, visit SpectronRx.com.
